A second inhibitor of the difficult-to-target KRAS protein was approved to treat certain lung cancers. The U.S. Food and Drug Administration (FDA) has granted accelerated approval to adagrasib (Krazati) for adult patients with locally...
The FDA approved the PD-L1 inhibitor atezolizumab to treat alveolar soft part sarcoma The U.S. Food and Drug Administration has approved atezolizumab (Tecentriq) for the treatment of patients 2 years of age or older...
A second inhibitor of mutant IDH1 was approved to treat certain blood cancers. The U.S. Food and Drug Administration (FDA) has approved olutasidenib (Rezlidhia) for patients with relapsed or refractory acute myeloid leukemia (AML)...
A targeted therapy was approved for a subset of treatment-resistant ovarian, fallopian tube, and peritoneal cancers. The U.S. Food and Drug Administration (FDA) has granted accelerated approval to mirvetuximab soravtansine-gynx (Elahere) for the treatment...
The FDA approved the immune checkpoint inhibitor tremelimumab to treat certain patients with non-small cell lung cancer. The U.S. Food and Drug Administration (FDA) has approved the immunotherapeutic tremelimumab (Imjudo) in combination with the...
The CD30-targeted antibody-drug conjugate was approved for some children with blood cancer. The U.S. Food and Drug Administration (FDA) has approved brentuximab vedotin (Adcetris) in combination with certain cancer therapies for pediatric patients over...
The immune checkpoint inhibitor cemiplimab-rwlc was approved in combination with chemotherapy for certain patients with non-small cell lung cancer. The U.S. Food and Drug Administration (FDA) has approved cemiplimab-rwlc (Libtayo) in combination with platinum-based...
The FDA granted accelerated approval to a targeted immunotherapy for patients with relapsed or refractory multiple myeloma. The U.S. Food and Drug Administration (FDA) has granted accelerated approval to teclistamab-cqyv (Tecvayli), a type of...
The FDA approved the combination of two checkpoint inhibitors for certain patients with hepatocellular carcinoma. The U.S. Food and Drug Administration (FDA) has approved tremelimumab (Imjudo) in combination with durvalumab (Imfinzi) for adult patients...
The FDA granted accelerated approval to a new targeted therapy for certain patients with advanced or metastatic cholangiocarcinoma. The U.S. Food and Drug Administration (FDA) has granted accelerated approval to futibatinib (Lytgobi) for adult...
AACR Fellow Lewis C. Cantley, PhD, leads a national effort targeting triple-negative breast cancer and ovarian cancer with a novel drug combination.
Learn MoreYour donation to the American Association for Cancer Research helps our more than 54,000 members worldwide drive progress against cancer.
Donate Now